



Approved for use through 03/31/2007. OMB 0551-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/595,935-Conf. #9193
		Filing Date	May 19, 2006
		First Named Inventor	Mladen Mercep
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	1	of	2
		Attorney Docket Number	03818/0204414-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/PEZ/	AA*	US-6,511,976	01-28-2003	Andres-Gil et al.	
	AB*	US-4,145,434	03-20-1979	VAN DER Burg et al.	
	AC*	US-3,711,489	01-16-1973	Lombardino	
	AD*	US-4,198,421	04-15-1980	Cherkofsky et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> Number <sup>2</sup> Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/PEZ/	BA	WO-99/19317	04-22-1999	JANSSEN PHARMACEUTICA NV	
	BB	WO-97/38991	10-23-1997	Janssen Pharmaceutica N.V.	
	BC	EP-0063525	10-27-1982	Centre National de la Recherche Scientifique	
	BD	WO-96/14320	05-17-1996	Janssen Pharmaceutica N.V.	
	BE	WO-96/14321	05-17-1996	Janssen Pharmaceutica N.V.	
	BF	CA-967,573	05-13-1975	Pfizer Inc.	
	BG	WO-03/097649	11-27-2003	PLIVA D D	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in performance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/PEZ/	CA	Berge S. M. et al. "Pharmaceutical Salts," Journal of Pharmaceutical Sciences., 1977, Vol. 66: pages 1-20			
	CB	Bonhaus D.W., et al., "The pharmacology and distribution of human 5-hydroxytryptamine <sub>2B</sub> (5-HT <sub>2B</sub> ) receptor gene products: comparison with 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors" British Journal of Pharmacology, (1999), Vol. 115: pages 622-628			
	CC	Sauder, C. et al. "Identification of an Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decreases in Receptor RNA and Number," Journal of Neurochemistry, 1997, vol 68, No. 3, pages 1998 - 2011			
	CD	Wolf, W.A. et al. "The Serotonin 5-HT <sub>2C</sub> Receptor is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin-Mediated Phosphoinositide Hydrolysis," Journal of Neurochemistry, 1997, vol. 69, pgs. 1449			
	CE	Thomson W., et al., "Juvenile Idiopathic Arthritis Genetics - What's new? What's next? Arthritis Research, 2002, vol. 4 and 5: pgs 302-306			
	CF	Millan, M.J. et al., "S18126 ((2-(2,3-dihydrobenzo[1,4] dioxin-6-yl)piperazin-1-yl)methyl), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In vitro and In Vitro and In Vivo Comparison with L 745,870 (3-(4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-			
Examiner Signature	/Paul Zarek/			Date Considered	01/01/2009



PTO/SB/08A/B (09-06)  
Approved for use through 03/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/595,935-Conf. #9193
		Filing Date	May 19, 2006
		First Named Inventor	Mladen Mercep
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	2	of	2
		Attorney Docket Number	03818/0204414-US0

		pyrrolo[2,3b]pyridine) and Radoipride, 1998, Journal of Pharmacology and Experimental Therapeutics, vol. 287, No. 1 pages 167-186.	
/PEZ	CG	Porsolt R.D. et al. "Behavioural Despair in Mice: A Primary Screening Test for Antidepressants" Arch. Int. Pharmacodyn. Vol. 229, pages 327-336 (1977)	
	CH	Niermegeers, C.J.E., et al., "Interaction of Drugs with Apomorphine, Tryptamine and Norepinephrine. A New 'in vivo' Approach: the ATN-Test in Rats", Arch. Int. Pharmacodyn. Vol. 227, pages 238-253 (1977).	
	CI	T.F. Meert, et al. "Psychopharmacology of Ritanerin: Comparison with Chlorthalidopexide", Drug Development Research, 1989, vol. 18, pgs.119-144	
	CJ	Becker H-D et al: "Photochemistry of the Anthracene Chromophore: Novel Isomerization of 1-(9-Anthryl)-2-Benzoyl ethylenes" Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, Vol. 26, no.12, 1985, pages 1589-1592.	
	CK	F.Bymaster, et al., "New Approaches to developing antidepressants by enhancing monoaminergic neurotransmission" Expert Opinion Investig. Drugs 2003, 12, 531-543	
	CL	U. Spampinato, et al. "Role of Striatal Serotonin 2A and Serotonin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum" J. Neurochemistry 2000, vol. 74, pgs. 693-701	
	CM	F.P. Monnet, et al. "N-Methyl-D-aspartate-induced neuronal activation is selectively modulated by $\alpha$ receptors", European Journal of Pharmacology, 1990, vol. 179, pgs. 441-445.	
	CN	Claghorn, J. et al, "Recent developments in antidepressant agents" Progress in Drug Research Clininc Inc. 1996, vol.46, pgs.243-262;	
	CO	Sperting, W. et al "New Tetracyclic Antidepressants" Drugs Today, 1997, vol. 33, No. 2, pgs. 95-102.	
	CP	J. Ignacio Andres et al. "R107500.A new 5-HT 2A/2C Antagonist with Potential Anxiolytic Profile" Drugs Fut. 2002, vol. 27, Suppl. A: C41	
	CQ	Jose M. Cid, et al., "Synthesis of 2-aminomethyl-3, 3a, 8, 12," Drugs Fut. 2002, vol 27, Suppl. A: P182	
✓	CR	PCT International Search Report for International Application No. PCT/HR2004/000052, dated April 18, 2005.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Paul Zarek/	Date Considered	01/01/2009
-----------------------	--------------	--------------------	------------